OBJECTIVE: Elevated YKL-40 concentrations have been observed in both coronary heart disease (CHD) and diabetes. Thus, YKL-40 may play a role in pathogenesis of CHD in patients with diabetes. We evaluated whether plasma YKL-40 concentration can predict all-cause and cardiovascular mortality in individuals with type 2 diabetes. DESIGN: This is a prospective, observational study. PATIENTS: A total of 628 subjects with type 2 diabetes were recruited between July 1996 and June 2003. MEASUREMENTS: Plasma YKL-40 concentrations were measured via enzyme-linked immunosorbent assay (ELISA). The cohort was followed up until 31 December 2008, when vital status and causes of death were obtained. Survival analysis and concordance statistics were performed. All-cause and cardiovascular mortalities were documented. RESULTS: There were 153 (24·36%) mortalities, including 48 participants (7·64%) who died from cardiovascular diseases (CVDs). Participants with higher plasma YKL-40 (defined with a level above the median of 87·5 μg/l) had an increased risk of mortality. After adjusting for confounding variables, the hazard ratios (HR) for all-cause and cardiovascular mortality in participants with higher plasma YKL-40 were 1·97 (95% CI, 1·31-2·95, P < 0·01) and 2·45 (95% CI, 1·11-5·37, P < 0·05). The results remained similar after adjustment for age. Concordance statistics revealed that plasma YKL-40 concentration significantly increases the predictive power for both all-cause and cardiovascular mortality in different models. CONCLUSIONS: Plasma YKL-40 concentration is an independent predictor of 10-year all-cause and cardiovascular mortality in subjects with type 2 diabetes. Further investigations on the role of YKL-40 in the pathogenesis of CVD are required to elucidate the underlying mechanisms.
OBJECTIVE: Elevated YKL-40 concentrations have been observed in both coronary heart disease (CHD) and diabetes. Thus, YKL-40 may play a role in pathogenesis of CHD in patients with diabetes. We evaluated whether plasma YKL-40 concentration can predict all-cause and cardiovascular mortality in individuals with type 2 diabetes. DESIGN: This is a prospective, observational study. PATIENTS: A total of 628 subjects with type 2 diabetes were recruited between July 1996 and June 2003. MEASUREMENTS: Plasma YKL-40 concentrations were measured via enzyme-linked immunosorbent assay (ELISA). The cohort was followed up until 31 December 2008, when vital status and causes of death were obtained. Survival analysis and concordance statistics were performed. All-cause and cardiovascular mortalities were documented. RESULTS: There were 153 (24·36%) mortalities, including 48 participants (7·64%) who died from cardiovascular diseases (CVDs). Participants with higher plasma YKL-40 (defined with a level above the median of 87·5 μg/l) had an increased risk of mortality. After adjusting for confounding variables, the hazard ratios (HR) for all-cause and cardiovascular mortality in participants with higher plasma YKL-40 were 1·97 (95% CI, 1·31-2·95, P < 0·01) and 2·45 (95% CI, 1·11-5·37, P < 0·05). The results remained similar after adjustment for age. Concordance statistics revealed that plasma YKL-40 concentration significantly increases the predictive power for both all-cause and cardiovascular mortality in different models. CONCLUSIONS: Plasma YKL-40 concentration is an independent predictor of 10-year all-cause and cardiovascular mortality in subjects with type 2 diabetes. Further investigations on the role of YKL-40 in the pathogenesis of CVD are required to elucidate the underlying mechanisms.
Authors: Julia Kzhyshkowska; Alexandru Gudima; Kondaiah Moganti; Alexei Gratchev; Alexander Orekhov Journal: Transfus Med Hemother Date: 2016-03-15 Impact factor: 3.747
Authors: Andrea L Conroy; Michael T Hawkes; Robyn Elphinstone; Robert O Opoka; Sophie Namasopo; Christopher Miller; Chandy C John; Kevin C Kain Journal: Malar J Date: 2018-02-15 Impact factor: 2.979
Authors: Alexandra Gkourogianni; Ioanna Kosteria; Aristeidis G Telonis; Alexandra Margeli; Emilia Mantzou; Maria Konsta; Dimitrios Loutradis; George Mastorakos; Ioannis Papassotiriou; Maria I Klapa; Christina Kanaka-Gantenbein; George P Chrousos Journal: PLoS One Date: 2014-04-11 Impact factor: 3.240